Validation of Minnesota acute graft-versus-host disease Risk Score
Margaret L. MacMillan,
Todd E. DeFor,
Shernan G. Holtan,
Armin Rashidi,
Bruce R. Blazar,
Daniel J. Weisdorf
Affiliations
Margaret L. MacMillan
Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN;Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN
Todd E. DeFor
Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN;Biostatistics and Informatics Core, Masonic Cancer Center, University of Minnesota Medical School, Minneapolis, MN
Shernan G. Holtan
Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN;Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
Armin Rashidi
Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN;Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
Bruce R. Blazar
Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN;Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN
Daniel J. Weisdorf
Blood and Marrow Transplant Program, University of Minnesota Medical School, Minneapolis, MN;Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
Using multicenter data, we developed a novel acute graft-versus-host disease Risk Score which more accurately predicts response to steroid treatment, survival and transplant related mortality than other published risk scores based upon clinical grading criteria.1 To validate this Risk Score in a contemporary cohort, we examined 355 recent University of Minnesota patients (2007-2016) diagnosed with acute graft-versus-host disease and treated with prednisone 60 mg/m2/day for 14 days, followed by an 8-week taper. Overall response [complete response + partial response] was higher in the 276 standard risk versus 79 high risk graft-versus-host disease patients at day 14 (71% versus 56%, P
